Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What's new in blistering disorders?

Paru Chaudhari1, M Peter Marinkovich

  • 1Stanford University School of Medicine and VA Palo Alto Medical Center, 269 Campus Drive, Room 2145, Stanford, CA 94061, USA.

Current Allergy and Asthma Reports
|June 6, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond Hematology-Current Insights into Chimeric Antigen Receptor (CAR) T-Cell Therapy for Skin and Connective Tissue Disorders.

Cells·2026
Same author

Observations of dystrophic epidermolysis bullosa patients with collagen VII NC2 truncation provide new insights into anchoring fibril assembly.

Matrix biology : journal of the International Society for Matrix Biology·2026
Same author

An evaluation of prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis bullosa.

Expert opinion on biological therapy·2026
Same author

Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.

Lancet (London, England)·2025
Same author

Correction to: Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa.

American journal of clinical dermatology·2025
Same author

Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa.

American journal of clinical dermatology·2025

Recent advances in autoimmune bullous diseases offer new insights into pathogenesis and treatment. This review covers key developments in diagnosing and managing pemphigus, pemphigoid, epidermolysis bullosa acquisita, and IgA-mediated disorders.

Area of Science:

  • Dermatology
  • Immunology
  • Pathogenesis

Background:

  • Autoimmune bullous diseases (AIBDs) represent a group of rare, chronic skin blistering conditions.
  • Significant progress has been made in understanding the underlying mechanisms and developing novel therapeutic strategies.
  • Recent years have witnessed revolutionary changes in the study and management of AIBDs.

Purpose of the Study:

  • To provide a comprehensive overview of recent advancements in the field of autoimmune bullous diseases.
  • To highlight key developments in diagnosis, pathogenesis, and treatment options.
  • To review significant progress in pemphigus, pemphigoid, epidermolysis bullosa acquisita, and immunoglobulin A-mediated disorders.

Main Methods:

  • Literature review of recent scientific publications.

Related Experiment Videos

  • Synthesis of information on new diagnostic tools and techniques.
  • Analysis of emerging therapeutic modalities and their clinical applications.

    • Main Results:

    • Characterization of new animal models aiding disease pathogenesis studies.
    • Demonstration of novel therapeutic approaches showing promise.
    • Significant improvements in diagnostic accuracy and speed.
    • Enhanced understanding of the immunopathogenesis of various AIBDs.

    Conclusions:

    • The field of autoimmune bullous diseases has been significantly advanced by recent research.
    • New diagnostic and therapeutic strategies offer improved patient outcomes.
    • Continued research is crucial for further understanding and managing these complex conditions.